These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20232116)

  • 1. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.
    Kagan L; Abraham AK; Harrold JM; Mager DE
    Pharm Res; 2010 May; 27(5):920-32. PubMed ID: 20232116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations.
    Lave T; Levet-Trafit B; Schmitt-Hoffmann AH; Morgenroth B; Richter W; Chou RC
    J Pharm Sci; 1995 Nov; 84(11):1285-90. PubMed ID: 8587044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice.
    Abraham AK; Kagan L; Kumar S; Mager DE
    J Pharmacol Exp Ther; 2010 Jul; 334(1):327-32. PubMed ID: 20406858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys.
    Mager DE; Neuteboom B; Efthymiopoulos C; Munafo A; Jusko WJ
    J Pharmacol Exp Ther; 2003 Jul; 306(1):262-70. PubMed ID: 12660309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
    Liu D; Ma X; Liu Y; Zhou H; Shi C; Wu F; Jiang J; Hu P
    Eur J Pharm Sci; 2016 Jun; 89():73-82. PubMed ID: 27108678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
    Larsen MS; Juul RV; Groth AV; Simonsson USH; Kristensen AT; Knudsen T; Agersø H; Kreilgaard M
    Eur J Pharm Sci; 2018 Mar; 115():196-203. PubMed ID: 29369801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.
    Hu X; Olivier K; Polack E; Crossman M; Zokowski K; Gronke RS; Parker S; Li Z; Nestorov I; Baker DP; Clarke J; Subramanyam M
    J Pharmacol Exp Ther; 2011 Sep; 338(3):984-96. PubMed ID: 21690216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice.
    McKenna SD; Vergilis K; Arulanandam AR; Weiser WY; Nabioullin R; Tepper MA
    J Interferon Cytokine Res; 2004 Feb; 24(2):119-29. PubMed ID: 14980076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interspecies modeling and prediction of human exenatide pharmacokinetics.
    Chen T; Mager DE; Kagan L
    Pharm Res; 2013 Mar; 30(3):751-60. PubMed ID: 23229855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
    Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
    Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
    Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
    Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
    Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin.
    Woo S; Jusko WJ
    Drug Metab Dispos; 2007 Sep; 35(9):1672-8. PubMed ID: 17576810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.
    Jaitin DA; Roisman LC; Jaks E; Gavutis M; Piehler J; Van der Heyden J; Uze G; Schreiber G
    Mol Cell Biol; 2006 Mar; 26(5):1888-97. PubMed ID: 16479007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys.
    Mager DE; Neuteboom B; Jusko WJ
    Pharm Res; 2005 Jan; 22(1):58-61. PubMed ID: 15771230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor.
    Titze MI; Schaaf O; Hofmann MH; Sanderson MP; Zahn SK; Quant J; Lehr T
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):545-558. PubMed ID: 28243682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon-alpha (PEG-CIFN) in rhesus monkeys.
    Du Y; Tian H; Gao XD; Yao WB
    Biopharm Drug Dispos; 2008 Nov; 29(8):481-4. PubMed ID: 18985796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.
    Piehler J; Schreiber G
    J Mol Biol; 1999 Nov; 294(1):223-37. PubMed ID: 10556041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species.
    Riviere JE; Martin-Jimenez T; Sundlof SF; Craigmill AL
    J Vet Pharmacol Ther; 1997 Dec; 20(6):453-63. PubMed ID: 9430769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers.
    Buchwalder PA; Buclin T; Trinchard I; Munafo A; Biollaz J
    J Interferon Cytokine Res; 2000 Oct; 20(10):857-66. PubMed ID: 11054273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.